VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for VBI Vaccines in a research report issued on Tuesday, March 14th. Jefferies Financial Group analyst R. Song expects that the biopharmaceutical company will post earnings of ($0.07) per share for the quarter. The consensus estimate for VBI Vaccines’ current full-year earnings is ($0.28) per share. Jefferies Financial Group also issued estimates for VBI Vaccines’ Q2 2023 earnings at ($0.07) EPS, Q3 2023 earnings at ($0.07) EPS, FY2023 earnings at ($0.26) EPS, FY2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.10) EPS.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last issued its quarterly earnings data on Monday, March 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). VBI Vaccines had a negative return on equity of 115.47% and a negative net margin of 10,471.63%. The business had revenue of $0.29 million for the quarter, compared to analysts’ expectations of $1.98 million.
VBI Vaccines Stock Down 9.0 %
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of VBIV. Engineers Gate Manager LP bought a new stake in VBI Vaccines in the 1st quarter worth approximately $26,000. Alliancebernstein L.P. lifted its position in VBI Vaccines by 9.9% in the 3rd quarter. Alliancebernstein L.P. now owns 188,900 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 17,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in VBI Vaccines by 8.8% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 267,148 shares of the biopharmaceutical company’s stock worth $443,000 after buying an additional 21,587 shares during the last quarter. Voya Investment Management LLC lifted its position in VBI Vaccines by 29.7% in the 4th quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 21,824 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in VBI Vaccines by 30.1% in the 3rd quarter. SG Americas Securities LLC now owns 100,345 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 23,234 shares during the last quarter. Hedge funds and other institutional investors own 38.24% of the company’s stock.
About VBI Vaccines
VBI Vaccines, Inc is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response.
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.